Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Ribozyme, Elan in JV to develop treatment for breast cancer

15 Apr 2003

Executive Summary

Ribozyme (develops ribozyme therapeutics) and Elan Pharmaceutical Technologies have formed a joint venture to research, develop, and possibly market Ribozyme's Herzyme against human epidermal growth factor receptor type 2 (HER-2) for the treatment of breast and other cancers.
Deal Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Joint Venture

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By